- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04832776
FOLFOXIRI Plus Cetuximab Versus FOLFOXIRI Plus Bevacizumab in Conversion Therapy of Right-sided Colon Cancer Liver Metastases
April 5, 2021 updated by: Sanjun Cai, Fudan University
To compare the efficacy of FOLFOXIRI plus Cetuximab and FOLFOXIRI plus Bevacuzumab in the conversion therapy of right-sided colon cancer liver metastases
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
160
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Wenhua Li
- Phone Number: 13817922257 13817922257
- Email: whliiris@hotmail.com
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200032
- Recruiting
- Department of Colorectal Surgery Fudan University Shanghai Cancer Center
-
Contact:
- Sanjun Cai, M.D
- Phone Number: 81108 +86-21-64175590
- Email: caisanjuncsj@163.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 73 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- ECOG perfomance 0-1
- pathologically confirmed colorectal carcinoma, with RAS wild type
- inital unresectable liver metastases discussed by MDT
- prior no systemical therapy or exceed 6 months after the adjuvant chemotherapy of primary tumor surgery.
- without extraheptic metastatic lesions, except for locally controlled lung metastases (RFA or SBRT)
- adequate blood, liver and renal function
- expected survival longer than 6 months
Exclusion Criteria:
- with bleeding risk
- interestinal obstruction or disease
- uncontrolled hypertension and severe heart disease
- previous severe thrombotic events
- central nervous system metastases
- accompanied with other malignant tumor
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: FOLFOXIRI+C225
|
one group plus cetuximab
FOLFOXIRI
|
Active Comparator: FOLFOXIRI+BEV
|
FOLFOXIRI
one group plus bevacizumab
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
ORR
Time Frame: up to 8 weeks
|
objective response rate
|
up to 8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
R0 resection rate of liver metastases
Time Frame: up to 8 weeks
|
R0 resection rate of liver metastases
|
up to 8 weeks
|
NED rate
Time Frame: up to 8 weeks
|
percentage of patients who reach NED
|
up to 8 weeks
|
OS
Time Frame: up to 6 months
|
overal survival
|
up to 6 months
|
PFS
Time Frame: up to 8 weeks
|
progression free survival
|
up to 8 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Wen Zhang, Fudan University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
April 17, 2021
Primary Completion (Anticipated)
December 31, 2023
Study Completion (Anticipated)
December 31, 2025
Study Registration Dates
First Submitted
April 2, 2021
First Submitted That Met QC Criteria
April 5, 2021
First Posted (Actual)
April 6, 2021
Study Record Updates
Last Update Posted (Actual)
April 6, 2021
Last Update Submitted That Met QC Criteria
April 5, 2021
Last Verified
April 1, 2021
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- Neoplasms
- Neoplasms by Site
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Liver Diseases
- Colonic Diseases
- Intestinal Diseases
- Intestinal Neoplasms
- Neoplastic Processes
- Colorectal Neoplasms
- Neoplasm Metastasis
- Liver Neoplasms
- Colonic Neoplasms
- Physiological Effects of Drugs
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Bevacizumab
- Cetuximab
Other Study ID Numbers
- Cetu-Bev-FOLFOXIRI
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Liver Metastasis Colon Cancer
-
Memorial Sloan Kettering Cancer CenterRecruitingColorectal Cancer | Colon Cancer | Liver Metastasis Colon Cancer | Adenocarcinoma of the Rectum | Colon Cancer Liver Metastasis | Adenocarcinoma of the ColonUnited States
-
McGill University Health Centre/Research Institute...RecruitingLiver Dysfunction | Liver Metastasis Colon Cancer | Liver RegenerationCanada
-
Lawson Health Research InstituteBayerRecruiting
-
AllVascularRecruitingLiver Metastasis Colon CancerAustralia
-
University of ManchesterManchester University NHS Foundation Trust; The Christie NHS Foundation Trust; Perspect... and other collaboratorsUnknownCancer | Colorectal Cancer | Liver Metastasis Colon Cancer | Cancer MetastaticUnited Kingdom
-
Western University, CanadaNot yet recruitingNAFLD | Liver Metastasis Colon Cancer | Liver Steatoses
-
International Group of Endovascular OncologyCompletedObservational Study on Second Line Treatment of Liver Metastases With DEBIRI and Cetuximab (TACETUX)Colon Cancer Liver MetastasisItaly
-
First Affiliated Hospital, Sun Yat-Sen UniversityNot yet recruitingLiver Metastasis Colon CancerChina
-
University of LeedsNational Cancer Institute (NCI); Massachusetts General Hospital; Massachusetts... and other collaboratorsRecruitingColon Cancer Liver MetastasisUnited Kingdom
-
PerspectumActive, not recruitingLiver Cancer | Liver Metastasis Colon CancerUnited Kingdom
Clinical Trials on Cetuximab
-
University Medical Center GroningenUMC Utrecht; Erasmus Medical CenterRecruitingHead and Neck Squamous Cell Carcinoma | Margin AssessmentNetherlands
-
West China HospitalFirst Affiliated Hospital of Chongqing Medical UniversityRecruitingColo-rectal Cancer | Capecitabine | CetuximabChina
-
Amsterdam UMC, location VUmcRadboud University Medical Center; University Medical Center GroningenTerminatedMetastatic Colorectal CancerNetherlands
-
Eben RosenthalNational Cancer Institute (NCI)TerminatedPancreatic AdenocarcinomaUnited States
-
HiberCell, Inc.TerminatedColorectal CancerUnited States, Puerto Rico, Germany, France
-
Merck KGaA, Darmstadt, GermanyCompletedPreviously Untreated Metastatic Colorectal CancerFrance, Italy, Poland, Germany, Hong Kong, Austria, Brazil, Israel, Greece, Argentina, Thailand, Belgium, Australia, Mexico
-
Arbeitsgemeinschaft medikamentoese TumortherapieMerck Sharp & Dohme LLCCompleted
-
Cancer Institute and Hospital, Chinese Academy...Recruiting
-
Poitiers University HospitalCompletedMetastatic Colon CancerFrance
-
Cliniques universitaires Saint-Luc- Université...Merck Sharp & Dohme LLC; Merck Serono International SACompleted